A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

This study is testing a new drug called 9MW2821 — alone and in combination with a PD-1 immune checkpoint inhibitor — in people with locally advanced or metastatic triple-negative breast cancer (TNBC), a type of breast cancer that lacks hormone receptors and HER2, making it harder to treat with targeted therapies. **You may be eligible if...** - You are 18 to 75 years old with confirmed locally advanced or metastatic triple-negative breast cancer - Your cancer is not suitable for surgery - You have either tried standard treatments that didn't work, or you have not yet received systemic therapy for advanced disease - Your overall health is good (ECOG 0–1) with adequate organ function **You may NOT be eligible if...** - You have uncontrolled brain metastases - You have active autoimmune disease - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.